Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CERo Therapeutics Holdings ( (CERO) ) just unveiled an announcement.
CERo Therapeutics, an innovative immunotherapy company, has appointed Chris Ehrlich as the new CEO, highlighting his extensive industry experience. Ehrlich aims to advance CERo’s pioneering T cell therapeutics, with plans to introduce CER-1236 into clinical trials for solid tumors and AML by early 2025. This strategic move underscores CERo’s commitment to revolutionizing cancer treatment through its unique CER-T technology, potentially offering broader applications than existing CAR-T therapies.
Learn more about CERO stock on TipRanks’ Stock Analysis page.
